Plain-English translation of NCT07448142 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three treatments for advanced rectal cancer: low-dose radiation therapy, an immunotherapy drug called , and chemotherapy drugs (CAPEOX). The study aims to see whether these treatments work together before surgery to shrink tumors and improve survival, especially for patients whose tumors don't respond well to immunotherapy alone.
Most patients with certain types of rectal cancer don't benefit much from immunotherapy by itself. Researchers believe that low-dose radiation might help 'wake up' the immune system to work better with the medication, potentially giving more patients a chance at better outcomes and even avoiding surgery altogether if the tumor shrinks enough.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of two low-dose radiation schedules combined with intravenous immunotherapy infusions every three weeks and oral chemotherapy pills, all before surgery. Over several months, you'll have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working. After treatment, your medical team will assess whether you can safely avoid surgery or proceed to an operation, based on how well the cancer responds.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China